Peraso (PRSO) 10-Q 13 May 21 2021 Q1 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - shares	3 Months Ended
	Mar. 31, 2021	May 07, 2021
Cover [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Mar. 31, 2021
Document Fiscal Year Focus	2021
Document Fiscal Period Focus	Q1
Entity Registrant Name	MOSYS, INC.
Entity Central Index Key	0000890394
Current Fiscal Year End Date	--12-31
Entity Filer Category	Non-accelerated Filer
Entity Current Reporting Status	Yes
Trading Symbol	MOSY
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Address, State or Province	CA
Entity Shell Company	false
Entity Interactive Data Current	Yes
Title of 12(b) Security	Common Stock, par value $0.001 per share
Security Exchange Name	NASDAQ
Entity Common Stock, Shares Outstanding		6,134,719
Entity File Number	000-32929
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	77-0291941
Entity Address, Address Line One	2309 Bering Drive
Entity Address, City or Town	San Jose
Entity Address, Postal Zip Code	95131
City Area Code	408
Local Phone Number	418-7500
Document Quarterly Report	true
Document Transition Report	false

CONDENSED CONSOLIDATED BALANCE

CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands	Mar. 31, 2021	Dec. 31, 2020
Current assets
Cash and cash equivalents	$ 9,529	$ 5,889
Short-term investments	1,610
Accounts receivable, net	375	701
Inventories	862	599
Prepaid expenses and other	534	668
Total current assets	12,910	7,857
Property and equipment, net	105	121
Right-of-use lease asset, net	254	303
Other	18	17
Total assets	13,287	8,298
Current liabilities
Accounts payable	81	76
Deferred revenue	15	15
Short-term lease liability	201	201
PPP note payable, current	434	244
Accrued expenses and other	1,291	1,300
Total current liabilities	2,022	1,836
Convertible notes payable		3,092
PPP note payable	145	335
Long-term lease liability	57	103
Total liabilities	2,224	5,366
Commitments and contingencies (Note 4)
Stockholders’ equity
Preferred stock, $0.01 par value; 20,000 shares authorized; none issued and outstanding
Common stock, $0.001 par value; 120,000 shares authorized; 6,134 shares and 3,554 shares issued and outstanding at March 31, 2021 and December 31, 2020, respectively	6	3
Additional paid-in capital	255,046	245,548
Accumulated other comprehensive loss	(1)
Accumulated deficit	(243,988)	(242,619)
Total stockholders’ equity	11,063	2,932
Total liabilities and stockholders’ equity	$ 13,287	$ 8,298

CONDENSED CONSOLIDATED BALANC_2

CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) - $ / shares	Mar. 31, 2021	Dec. 31, 2020
Statement Of Financial Position [Abstract]
Preferred stock, par value	$ 0.01	$ 0.01
Preferred stock, shares authorized	20,000,000	20,000,000
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0
Common stock, par value	$ 0.001	$ 0.001
Common stock, shares authorized	120,000,000	120,000,000
Common stock, shares issued	6,134,000	3,554,000
Common stock, shares outstanding	6,134,000	3,554,000

CONDENSED CONSOLIDATED STATEMEN

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS - USD ($) shares in Thousands, $ in Thousands	3 Months Ended
	Mar. 31, 2021	Mar. 31, 2020
Net revenue
Total net revenue	$ 1,338	$ 1,260
Cost of net revenue	495	530
Gross profit	843	730
Operating expenses
Research and development	1,159	961
Selling, general and administrative	1,071	1,135
Total operating expenses	2,230	2,096
Loss from operations	(1,387)	(1,366)
Interest expense	(30)	(55)
Other income, net	48	16
Net loss	(1,369)	(1,405)
Other comprehensive loss, net of tax:
Net unrealized loss on available-for-sale securities	(1)
Comprehensive loss	$ (1,370)	$ (1,405)
Net loss per share
Basic and diluted	$ (0.28)	$ (0.61)
Shares used in computing net loss per share
Basic and diluted	4,862	2,295
Product
Net revenue
Total net revenue	$ 1,178	$ 1,068
Royalty and Other
Net revenue
Total net revenue	$ 160	$ 192

CONDENSED CONSOLIDATED STATEM_2

CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY - USD ($) shares in Thousands, $ in Thousands	Total	Common Stock	Additional Paid-In Capital	Accumulated Other Comprehensive Loss	Accumulated Deficit
Beginning Balance at Dec. 31, 2019	$ 4,836	$ 2	$ 243,281		$ (238,447)
Beginning Balance, shares at Dec. 31, 2019		2,179
Issuance of common stock for release of awards	(1)		(1)
Issuance of common stock for release of awards, shares		20
Exercise of pre-funded warrants	2		2
Exercise of pre-funded warrants, shares		116
Stock-based compensation	68		68
Net loss	(1,405)				(1,405)
Ending Balance at Mar. 31, 2020	3,500	$ 2	243,350		(239,852)
Ending Balance, shares at Mar. 31, 2020		2,315
Beginning Balance at Dec. 31, 2020	$ 2,932	$ 3	245,548		(242,619)
Beginning Balance, shares at Dec. 31, 2020	3,554	3,554
Issuance of common stock under stock plan, net	$ (2)		(2)
Issuance of common stock under stock plan, net, shares		16
Exercise of warrants	2,478	$ 1	2,477
Exercise of warrants, shares		1,033
Issuance of common stock for payment of accrued interest	140		140
Issuance of common stock for payment of accrued interest,shares		43
Sale of common stock, net of placement costs	6,817	$ 2	6,815
Sale of common stock, net of placement costs,shares		1,488
Stock-based compensation	68		68
Unrealized loss on available-for-sale investments	(1)			$ (1)
Net loss	(1,369)				(1,369)
Ending Balance at Mar. 31, 2021	$ 11,063	$ 6	$ 255,046	$ (1)	$ (243,988)
Ending Balance, shares at Mar. 31, 2021	6,134	6,134

CONDENSED CONSOLIDATED STATEM_3

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)	3 Months Ended
	Mar. 31, 2021	Mar. 31, 2020
Cash flows from operating activities:
Net loss	$ (1,369,000)	$ (1,405,000)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	18,000	41,000
Stock-based compensation	68,000	68,000
Accrued interest	30,000	55,000
Amortization of lease right-of-use asset	49,000	47,000
Change in operating lease liability	(46,000)	(50,000)
Gain on settlement of convertible notes payable and accrued interest, net	(48,000)
Changes in assets and liabilities:
Accounts receivable	325,000	636,000
Inventories	(263,000)	(137,000)
Prepaid expenses and other assets	134,000	(35,000)
Accounts payable	5,000	(111,000)
Deferred revenue and other liabilities	84,000	183,000
Net cash used in operating activities	(1,013,000)	(708,000)
Cash flows from investing activities:
Purchases of property and equipment	(2,000)	(6,000)
Proceeds from maturities of short-term investments		300,000
Purchases of short-term investments	(1,611,000)
Net cash provided by (used in) investing activities	(1,613,000)	294,000
Cash flows from financing activities:
Proceeds from sale of common stock, net	6,817,000
Proceeds from exercise of common stock warrants	2,478,461	2,000
Repayment of convertible notes payable	(3,027,000)
Taxes paid to net share settle equity awards	(2,000)	(1,000)
Net cash provided by financing activities	6,266,000	1,000
Net increase (decrease) in cash and cash equivalents	3,640,000	(413,000)
Cash and cash equivalents at beginning of period	5,889,000	6,053,000
Cash and cash equivalents at end of period	9,529,000	5,640,000
Supplemental disclosure:
Issuance of convertible notes in settlement of accrued interest		$ 112,000
Settlement of accrued interest through issuance of common shares	$ 123,000

The Company and Summary of Sign

The Company and Summary of Significant Accounting Policies	3 Months Ended
	Mar. 31, 2021
Accounting Policies [Abstract]
The Company and Summary of Significant Accounting Policies	Note 1. The Company and Summary of Significant Accounting Policies MoSys, Inc. (the Company) was incorporated in California in 1991 and reincorporated in 2000 in Delaware. The Company provides both integrated circuits (ICs) and intellectual property (IP) solutions that enable fast, intelligent data access and decision making for a wide range of markets. The Company’s primary product line is marketed under the Accelerator Engine name and includes the Bandwidth Engine IC products, which integrate the Company’s proprietary, 1T-SRAM high-density embedded memory and a highly-efficient serial interface protocol resulting in a monolithic memory IC solution optimized for memory bandwidth and transaction access performance. Virtual Accelerator Engine products which consist of software, firmware and related IP. This new product line will include multiple function accelerator platform products, which target specific application functions and will use a common software interface to allow performance scalability over multiple hardware environments. The accompanying condensed consolidated financial statements of the Company have been prepared without audit. The condensed consolidated balance sheet as of December 31, 2020 has been derived from the audited consolidated financial statements at that date. Certain information and disclosures normally included in financial statements prepared in accordance with accounting principles generally accepted in the United States (GAAP) have been condensed or omitted in accordance with these rules and regulations of the Securities and Exchange Commission (SEC). The information in this report should be read in conjunction with the Company’s consolidated financial statements and notes thereto included in its most recent annual report on Form 10-K filed with the SEC. In the opinion of management, the accompanying unaudited condensed consolidated financial statements reflect all adjustments (consisting only of normal recurring adjustments) necessary to summarize fairly the Company’s financial position, results of operations and cash flows for the interim periods presented. The operating results for the three months ended March 31, 2021 are not necessarily indicative of the results that may be expected for the year ending December 31, 2021 or for any other future period. Basis of Presentation The condensed consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries. All significant intercompany transactions and balances have been eliminated in consolidation. The Company’s fiscal year ends on December 31 of each calendar year. Risks and Uncertainties The Company is subject to risks from, among other things, competition associated with the industry in general, other risks associated with financing, liquidity requirements, rapidly changing customer requirements, limited operating history and the volatility of public markets. COVID-19 The global outbreak of the coronavirus disease 2019 (COVID-19) was declared a pandemic by the World Health Organization and a national emergency by the U.S. government in March 2020. This has negatively affected the U.S. and global economy, disrupted global supply chains, significantly restricted travel and transportation, resulted in mandated closures and orders to “shelter-in-place” and created significant disruption of the financial markets. The full extent of the COVID-19 impact on the Company’s operational and financial performance will depend on future developments, including the duration and spread of the pandemic and related actions taken by U.S. and foreign government agencies to prevent disease spread, all of which are uncertain, out of the Company’s control, and cannot be predicted. Use of Estimates The preparation of financial statements in accordance with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses recognized during the reported period. Actual results could differ from those estimates. Cash Equivalents and Investments The Company has invested its excess cash in money market accounts, certificates of deposit, commercial paper, corporate debt, government-sponsored enterprise bonds and municipal bonds and considers all highly liquid debt instruments purchased with an original maturity of three months or less to be cash equivalents. Investments with original maturities greater than three months and remaining maturities less than one year are classified as short-term investments. Investments with remaining maturities greater than one year are classified as long-term investments. Management generally determines the appropriate classification of securities at the time of purchase. All securities are classified as available-for-sale. The Company’s available-for-sale short-term investments are carried at fair value, with the unrealized holding gains and losses reported in accumulated other comprehensive income. Realized gains and losses and declines in the value judged to be other than temporary are included in the other income, net line item in the condensed consolidated statements of operations and comprehensive loss. The cost of securities sold is based on the specific identification method. Fair Value Measurements The Company measures the fair value of financial instruments using a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value into three broad levels: Level 1— Inputs used to measure fair value are unadjusted quoted prices that are available in active markets for the identical assets or liabilities as of the reporting date. Level 2— Pricing is provided by third party sources of market information obtained through the Company’s investment advisors, rather than models. The Company does not adjust for, or apply, any additional assumptions or estimates to the pricing information it receives from advisors. The Company’s Level 2 securities may include cash equivalents and available-for-sale securities, which consist primarily of certificates of deposit, corporate debt, and government agency and municipal debt securities from issuers with high-quality credit ratings. The Company’s investment advisors obtain pricing data from independent sources, such as Standard & Poor’s, Bloomberg and Interactive Data Corporation, and rely on comparable pricing of other securities because the Level 2 securities are not actively traded and have fewer observable transactions. The Company considers this the most reliable information available for the valuation of the securities. Level 3— Unobservable inputs that are supported by little or no market activity and reflect the use of significant management judgment are used to measure fair value. These values are generally determined using pricing models for which the assumptions utilize management’s estimates of market participant assumptions. The determination of fair value for Level 3 investments and other financial instruments involves the most management judgment and subjectivity. Allowance for Doubtful Accounts The Company establishes an allowance for doubtful accounts to ensure that its trade receivables balances are not overstated due to uncollectibility. The Company performs ongoing customer credit evaluations within the context of the industry in which it operates and generally does not require collateral from its customers. A specific allowance of up to 100% of the invoice value is provided for any problematic customer balances. Delinquent account balances are written off after management has determined that the likelihood of collection is remote. The Company grants credit only to customers deemed creditworthy in the judgment of management. The allowance for doubtful accounts was $41,000 at March 31, 2021 and December 31, 2020. Inventories The Company values its inventories at the lower of cost, which approximates actual cost on a first-in, first-out basis, or net realizable value. The Company records inventory reserves for estimated obsolescence or unmarketable inventories based upon assumptions about future demand and market conditions. Once a reserve is established, it is maintained until the product to which it relates is sold or otherwise disposed of. If actual market conditions are less favorable than those expected by management, additional adjustment to inventory valuation may be required. Charges for obsolete and slow-moving inventories are recorded based upon an analysis of specific identification of obsolete inventory items and quantification of slow moving inventory items. The Company recorded no material write-downs of inventory during the three months ended March 31, 2021 and recorded write-downs of $0.1 million for the year ended December 31, 2020. Revenue Recognition The Company generates revenue primarily from sales of IC products and licensing of its IP. Revenues are recognized when control is transferred to customers in amounts that reflect the consideration the Company expects to be entitled to receive in exchange for those goods. Revenue recognition is evaluated through the following five steps: (i) identification of the contract, or contracts, with a customer; (ii) identification of the performance obligations in the contract; (iii) determination of the transaction price; (iv) allocation of the transaction price to the performance obligations in the contract; and (v) recognition of revenue when or as a performance obligation is satisfied. IC products Revenue is recognized when performance obligations under the terms of a contract with a customer are satisfied. The majority of the Company’s contracts have a single performance obligation to transfer products. Accordingly, the recognizes revenue when title and risk of loss have been transferred to the customer, generally at the time of shipment of products. Revenue is measured as the amount of consideration the Company expects to receive in exchange for transferring products and is generally based upon a negotiated, formula, list or fixed price. The Company its and generally under agreements with payment terms typically less than 60 days. Royalty and other The Company’s licensing contracts typically provide for royalties based on the licensee’s use of the Company’s memory technology in its currently shipping commercial products. The Company estimates its royalty revenue in the calendar quarter in which the licensee uses the licensed technology. Payments are generally received in the subsequent quarter. Contract liabilities – deferred revenue The Company’s contract liabilities consist of advance customer payments and deferred revenue. The Company classifies advance customer payments and deferred revenue as current or non-current based on the timing of when the Company expects to recognize revenue. During the three months ended March 31, 2021, the Company recognized no revenue that had been included in deferred revenue as of December 31, 2020. See Note 5 for disaggregation of revenue by geography. Cost of Net Revenue Cost of net revenue consists primarily of direct and indirect costs of IC product sales and engineering personnel costs directly related to maintenance and support services specified in licensing agreements. Maintenance and support typically include engineering support to assist in the commencement of production of a licensee’s products. Warrants As of March 31, 2021, the Company had the following warrants outstanding (share amounts in thousands): Warrant Type Number of Shares Exercise Price Expiration Common stock 33 $ 47.00 January 2023 Common stock 813 $ 2.40 October 2023 Per Share Amounts Basic net income (loss) per share is computed by dividing net income (loss) for the period by the weighted-average number of shares of common stock outstanding during the period. Diluted net income (loss) per share gives effect to all potentially dilutive shares of common stock outstanding during the period. Potentially dilutive shares of common stock consist of incremental shares of common stock issuable upon the exercise of stock options, vesting of stock awards and shares issuable in conjunction with convertible notes. The following table sets forth securities outstanding that were excluded from the computation of diluted net loss per share as their inclusion would be anti-dilutive (in thousands): March 31, 2021 2020 Options outstanding to purchase common stock 159 161 Unvested restricted common stock units 58 82 Convertible notes - 254 Warrants 846 1,879 Total 1,063 2,376

Fair Value of Financial Instrum

Fair Value of Financial Instruments	3 Months Ended
	Mar. 31, 2021
Fair Value Disclosures [Abstract]
Fair Value of Financial Instruments	Note 2: Fair Value of Financial Instruments The estimated fair values of financial instruments outstanding were (in thousands): March 31, 2021 Unrealized Unrealized Fair Cost Gains Losses Value Cash and cash equivalents $ 9,529 $ — $ — $ 9,529 Short-term investments 1,611 — (1 ) 1,610 $ 11,140 $ — $ (1 ) $ 11,139 December 31, 2020 Unrealized Unrealized Fair Cost Gains Losses Value Cash and cash equivalents $ 5,889 $ — $ — $ 5,889 The following table represents the Company’s fair value hierarchy for its financial assets (cash equivalents and investments) (in thousands): March 31, 2021 Fair Value Level 1 Level 2 Level 3 Money market funds $ 7,276 $ 7,276 $ — $ — Corporate notes and commercial paper $ 1,610 $ — $ 1,610 $ — December 31, 2020 Fair Value Level 1 Level 2 Level 3 Money market funds $ 3,893 $ 3,893 $ — $ — There were no transfers in or out of Level 1 and Level 2 securities during the three months ended March 31, 2021 or 2020.

Balance Sheet Detail

Balance Sheet Detail	3 Months Ended
	Mar. 31, 2021
Organization Consolidation And Presentation Of Financial Statements [Abstract]
Balance Sheet Detail	Note 3. Balance Sheet Detail March 31, December 31, 2021 2020 (in thousands) Inventories: Work-in-process $ 654 $ 414 Finished goods 208 185 $ 862 $ 599

Commitments and Contingencies

Commitments and Contingencies	3 Months Ended
	Mar. 31, 2021
Commitments And Contingencies Disclosure [Abstract]
Commitments and Contingencies	Note 4. Commitments and Contingencies Indemnification In the ordinary course of business, the Company enters into contractual arrangements under which it may agree to indemnify the counterparties from any losses incurred relating to breach of representations and warranties, failure to perform certain covenants, or claims and losses arising from certain events as outlined within the particular contract, which may include, for example, losses arising from litigation or claims relating to past performance. Such indemnification clauses may not be subject to maximum loss clauses. The Company has also entered into indemnification agreements with its officers and directors. No material amounts were reflected in the Company’s condensed consolidated financial statements for the three months ended March 31, 2021 or 2020 related to these indemnifications. The Company has not estimated the maximum potential amount of indemnification liability under these agreements due to the limited history of prior claims and the unique facts and circumstances applicable to each particular agreement. To date, the Company has not made any material payments related to these indemnification agreements. Legal Matters The Company is not a party to any legal proceeding that the Company believes is likely to have a material adverse effect on its condensed consolidated financial position or results of operations. From time to time the Company may be subject to legal proceedings and claims in the ordinary course of business. These claims, even if not meritorious, could result in the expenditure of significant financial resources and diversion of management efforts.

Business Segments, Concentratio

Business Segments, Concentration of Credit Risk and Significant Customers	3 Months Ended
	Mar. 31, 2021
Segment Reporting [Abstract]
Business Segments, Concentration of Credit Risk and Significant Customers	Note 5. Business Segments, Concentration of Credit Risk and Significant Customers The Company operates in one business segment and uses one measurement of profitability for its business. Net revenue is attributed to the United States and to all foreign countries based on the geographical location of the customer. The Company recognized revenue from shipment of product and licensing of its technologies to customers by geographical location as follows (in thousands): Three Months Ended March 31, 2021 2020 North America $ 948 $ 812 Japan 274 237 Taiwan 79 138 Rest of world 37 73 Total net revenue $ 1,338 $ 1,260 Customers who accounted for at least 10% of total net revenue were: Three Months Ended March 31, 2021 2020 Customer A 38% 26% Customer B 20% 19% Customer C 18% 14% Customer D *% 12% Customer E *% 11% * Represents less than 10% Three customers accounted for 74% of accounts receivable as of March 31, 2021. Three customers accounted for 86% of accounts receivable as of December 31, 2020.

Income Tax Provision

Income Tax Provision	3 Months Ended
	Mar. 31, 2021
Income Tax Disclosure [Abstract]
Income Tax Provision	Note 6. Income Tax Provision The Company determines deferred tax assets and liabilities based upon the differences between the financial statement and tax bases of the Company’s assets and liabilities using tax rates in effect for the year in which the Company expects the differences to affect taxable income. A valuation allowance is established for any deferred tax assets for which it is more likely than not that all or a portion of the deferred tax assets will not be realized. The Company files U.S. federal and state and foreign income tax returns in jurisdictions with varying statutes of limitations. All tax returns from 2014 to 2019 may be subject to examination by the Internal Revenue Service, California and other states. Returns filed in foreign jurisdictions may be subject to examination for the years 2010 to 2019. As of March 31, 2021, the Company has not recorded any liability for unrecognized tax benefits related to uncertain tax positions.

Stock-Based Compensation

Stock-Based Compensation	3 Months Ended
	Mar. 31, 2021
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]
Stock-Based Compensation	Note 7. Stock-Based Compensation Common Stock Equity Plans In 2010, the Company adopted the 2010 Equity Incentive Plan and later amended it in 2014, 2017 and 2018 (the Amended 2010 Plan). The Amended 2010 Plan was terminated in August 2019 and remains in effect as to outstanding equity awards granted prior to the date of expiration. As of March 31, 2021, no new awards may be made under the Amended 2010 Plan, and equity awards for approximately 57,858 shares were outstanding. In August 2019, the Company’s stockholders approved the 2019 Stock Incentive Plan (the 2019 Plan), and it replaced the Amended 2010 Plan. The 2019 Plan authorizes the board of directors or the compensation committee of the board of directors to grant a broad range of awards including stock options, stock appreciation rights, restricted stock, performance-based awards, and restricted stock units. Under the 2019 Plan, 182,500 shares have been reserved for issuance. The 2019 Plan provides for annual option grants or other awards to the Company’s non-employee directors to acquire up to 2,000 shares and for a one-time grant of an option or other award to a non-employee director to acquire up to 6,000 shares upon his or her initial appointment or election to the board of directors. Under the 2019 Plan, the term of all incentive stock options granted to a person who, at the time of grant, owns stock representing more than 10% of the voting power of all classes of the Company’s stock may not exceed five years. The exercise price of stock options granted under the 2019 Plan must be at least equal to the fair market value of the shares on the date of grant. Generally, awards under the 2019 Plan will vest over a three to four-year period, and options will have a term of 10 years from the date of grant. In addition, the 2019 Plan provides for automatic acceleration of vesting for options granted to non-employee directors upon a change of control of the Company. The Amended 2010 Plan and the 2019 Plan are referred to collectively as the “Plans.” The expense relating to stock options is recognized on a straight-line basis over the requisite service period, usually the vesting period, based on the grant-date fair value. The unamortized compensation cost, as of March 31, 2021, was $0.1 million related to stock options and is expected to be recognized as expense over a weighted-average period of approximately 1.25 years. The expense related to restricted stock units (RSUs) is generally recognized over a three-year vesting period and is based on the fair value of the underlying stock on the dates of grant. The unamortized compensation cost, as of March 31, 2021, was $0.2 million related to RSUs and is expected to be recognized as expense over a weighted-average period of approximately 0.5 years. For the three months ended March 31, 2021 and 2020, there were no excess tax benefits associated with the exercise of stock options due to the Company’s historical loss positions. Valuation Assumptions There were no stock options granted during the three months ended March 31, 2021 and 2020. Common Stock Options and Restricted Stock The term of all incentive stock options granted to a person who, at the time of grant, owns stock representing more than 10% of the voting power of all classes of the Company’s stock may not exceed five years. The exercise price of stock options granted under the 2019 Plan must be at least equal to the fair market value of the shares on the date of grant. Generally, options granted under the 2019 Plan will vest over a three to four-year period and have a term of 10 years from the date of grant. In addition, the 2019 Plan provides for automatic acceleration of vesting for options granted to non-employee directors upon a change of control of the Company. The following table summarizes the activity in the shares available for grant under the Plans during the three months ended March 31, 2021 (in thousands, except exercise price): Options outstanding Weighted Shares Average Available Number of Exercise for Grant Shares Prices Balance as of January 1, 2021 81 159 $ 10.82 RSUs granted (10 ) — — Balance as of March 31, 2021 71 159 $ 10.82 A summary of RSU activity under the Plans is presented below (in thousands, except for fair value): Weighted Average Number of Grant-Date Shares Fair Value Non-vested shares as of January 1, 2021 65 $ 3.48 Granted 10 $ 3.25 Vested (17 ) $ 3.78 Non-vested shares as of March 31, 2021 58 $ 3.35 The fair value of the RSU granted during the three months ended March 31, 2021 was $32,500. The total intrinsic value of the RSUs outstanding as of March 31, 2021 was $0.2 million. The following table summarizes significant ranges of outstanding and exercisable options as of March 31, 2021 (in thousands, except contractual life and exercise price): Options Outstanding Options Exercisable Weighted Average Remaining Weighted Weighted Contractual Average Average Aggregate Number Life Exercise Number Exercise Intrinsic Range of Exercise Price Outstanding (in Years) Price Exercisable Price value $1.57 - $14.99 143 8.01 $ 2.62 79 $ 2.88 $ 185 $15.00 - $25.59 8 2.49 $ 15.00 8 $ 15.00 $ — $25.60 - $143.99 2 3.11 $ 41.81 2 $ 41.81 $ — $144.00 - $409.99 5 5.40 $ 144.00 5 $ 144.00 $ — $410.00 - $924.00 1 3.94 $ 430.64 1 $ 430.64 $ — $1.57 - $924.00 159 8.04 $ 10.82 95 $ 16.55 $ 185 There were no stock options exercised during the three months ended March 31, 2021 or 2020.

Stockholders' Equity

Stockholders' Equity	3 Months Ended
	Mar. 31, 2021
Stockholders Equity Note [Abstract]
Stockholders' Equity	Note 8: Stockholders’ Equity In February 2021, the Company completed a registered direct offering of securities under an effective registration statement filed with the SEC pursuant to the Securities Act of 1933, as amended. In the offering, the Company sold 1,487,601 shares of common stock at a price of $5.00 per share to institutional investors. Net proceeds of the offering, after placement agent and other fees and expenses paid by the Company, were approximately $6.8 million. During the three months ended March 31, 2021, the Company received a total of $2,478,461 of proceeds from the exercise of 1,032,692 warrants to purchase shares of common stock at a price of $2.40 per share.

Notes Payable

Notes Payable	3 Months Ended
	Mar. 31, 2021
Debt Disclosure [Abstract]
Notes Payable	Note 9. Notes Payable Convertible Notes In March 2016, the Company entered into a 10% Senior Secured Convertible Note Purchase Agreement (the Purchase Agreement) with the purchasers of $8,000,000 principal amount of 10% Senior Secured Convertible Notes due August 15, 2018 (the Notes), at par, in a private placement transaction effected pursuant to an exemption from the registration requirements under the Securities Act of 1933, as amended. Pursuant to amendments to the Notes and related documents in February and October 2018, the interest rate was reduced to 8%, the maturity date of the Notes was extended to August 15, 2023, and the optional conversion price was reduced from $170.00 of Note principal per share of common stock to $11.434 of Note principal per share of common stock. In accordance with the October 2018 amendment to the Notes, the Company used $7.4 million of the proceeds from a public offering of securities effected in October 2018 to repay a portion of the Notes. Semi-annual interest payments have been made in each of February 2019, August 2019, February 2020 and August 2020 for approximately $78,000, $109,000, $112,000 and $122,000, respectively, in-kind with the issue of additional notes (Interest Notes) to the Purchasers. The Interest Notes have terms identical to the Notes. The Company issued 42,672 shares of its common stock valued at $139,964 to the Note holder in settlement of the accrued interest for the six month period ended February 15, 2021. The Company recorded a loss of $16,898 on this payment, which was recorded in other income in the condensed consolidated statements of operation. In January and February 2021, a holder of warrants, who was also the holder of the Notes, exercised warrants to purchase 613,791 shares of the Company’s common stock at an exercise price of $2.40 per share for total proceeds of $1,473,098. The proceeds from the exercise of these warrants were used to repay a portion of the principal amount of the Notes. In March 2021, the Company made a repayment of $1,554,173 in settlement of the outstanding principal amount of the Notes, and the Note holder’s security interest was terminated. The Company recorded a gain of $64,757 on the Note settlement, and the gain was recorded in other income in the condensed consolidated statements of operations. PPP Note On May 7, 2020, the Company entered into a Promissory Note with Wells Fargo Bank, N.A. (the Lender) in an aggregate principal amount of $579,330 (the PPP Note), pursuant to the Paycheck Protection Program (the PPP) under the CARES Act. The term of the PPP Note is two years. Interest will accrue on the outstanding principal balance of the PPP Note at a fixed rate of 1.0%, which shall be deferred for the first ten months of the term of the PPP Note. Monthly payments will be due and payable beginning in March 2021 and continue each month thereafter until maturity of the PPP Note. The Company may prepay principal of the PPP Note at any time in any amount without penalty. The Agreement contains customary events of default relating to, among other things, payment defaults, breach of representations and warranties or provisions of the PPP Note. The occurrence of an event of default may result in the repayment of all amounts outstanding, collection of all amounts owing from the Company, and/or filing suit and obtaining judgment against the Company. The Company applied to the Lender for forgiveness of the PPP Note, under the terms of the PPP. No assurance is provided that the Company will obtain forgiveness of the PPP Note in whole or in part, but the Company believes it has used the proceeds in accordance with the PPP. If the PPP Note is not forgiven, principal payments will be due: $217,250 in 2021 and $362,080 in 2022.

Leases

Leases	3 Months Ended
	Mar. 31, 2021
Leases [Abstract]
Leases	Note 10. Leases The Company has one lease, which is the lease for its corporate facility that expires in July 2022, that it accounts for under Accounting Standards Update 2016-02. The right-of-use asset and corresponding liability for the facility lease have been measured at the present value of the future minimum lease payments. The discount rate used to measure the lease asset and liability represents the interest rate on the Notes (8%). Lease expense is recognized on a straight-line basis over the lease term, and operating lease expense was approximately $53,000 for the three months ended March 31, 2021. The Company does not have an option to extend the lease term beyond the current extension. Future minimum payments under the facility operating lease at March 31, 2021 are as follows (in thousands): Operating Year ending December 31, lease 2021 $ 155 2022 112 Total future lease payments 267 Less: imputed interest (9 ) Present value of lease liabilities $ 258 Supplemental cash flow information related to the operating lease was as follows (in thousands): Three Months Ended March 31, 2021 2020 Cash paid for amounts included in the measurement of lease liabilities: Operating cash flows for lease $ 51 $ 56

The Company and Summary of Si_2

The Company and Summary of Significant Accounting Policies (Policies)	3 Months Ended
	Mar. 31, 2021
Accounting Policies [Abstract]
Basis of Presentation	Basis of Presentation The condensed consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries. All significant intercompany transactions and balances have been eliminated in consolidation. The Company’s fiscal year ends on December 31 of each calendar year.
Risks and Uncertainties	Risks and Uncertainties The Company is subject to risks from, among other things, competition associated with the industry in general, other risks associated with financing, liquidity requirements, rapidly changing customer requirements, limited operating history and the volatility of public markets. COVID-19 The global outbreak of the coronavirus disease 2019 (COVID-19) was declared a pandemic by the World Health Organization and a national emergency by the U.S. government in March 2020. This has negatively affected the U.S. and global economy, disrupted global supply chains, significantly restricted travel and transportation, resulted in mandated closures and orders to “shelter-in-place” and created significant disruption of the financial markets. The full extent of the COVID-19 impact on the Company’s operational and financial performance will depend on future developments, including the duration and spread of the pandemic and related actions taken by U.S. and foreign government agencies to prevent disease spread, all of which are uncertain, out of the Company’s control, and cannot be predicted.
Use of Estimates	Use of Estimates The preparation of financial statements in accordance with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses recognized during the reported period. Actual results could differ from those estimates.
Cash Equivalents and Investments	Cash Equivalents and Investments The Company has invested its excess cash in money market accounts, certificates of deposit, commercial paper, corporate debt, government-sponsored enterprise bonds and municipal bonds and considers all highly liquid debt instruments purchased with an original maturity of three months or less to be cash equivalents. Investments with original maturities greater than three months and remaining maturities less than one year are classified as short-term investments. Investments with remaining maturities greater than one year are classified as long-term investments. Management generally determines the appropriate classification of securities at the time of purchase. All securities are classified as available-for-sale. The Company’s available-for-sale short-term investments are carried at fair value, with the unrealized holding gains and losses reported in accumulated other comprehensive income. Realized gains and losses and declines in the value judged to be other than temporary are included in the other income, net line item in the condensed consolidated statements of operations and comprehensive loss. The cost of securities sold is based on the specific identification method.
Fair Value Measurements	Fair Value Measurements The Company measures the fair value of financial instruments using a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value into three broad levels: Level 1— Inputs used to measure fair value are unadjusted quoted prices that are available in active markets for the identical assets or liabilities as of the reporting date. Level 2— Pricing is provided by third party sources of market information obtained through the Company’s investment advisors, rather than models. The Company does not adjust for, or apply, any additional assumptions or estimates to the pricing information it receives from advisors. The Company’s Level 2 securities may include cash equivalents and available-for-sale securities, which consist primarily of certificates of deposit, corporate debt, and government agency and municipal debt securities from issuers with high-quality credit ratings. The Company’s investment advisors obtain pricing data from independent sources, such as Standard & Poor’s, Bloomberg and Interactive Data Corporation, and rely on comparable pricing of other securities because the Level 2 securities are not actively traded and have fewer observable transactions. The Company considers this the most reliable information available for the valuation of the securities. Level 3— Unobservable inputs that are supported by little or no market activity and reflect the use of significant management judgment are used to measure fair value. These values are generally determined using pricing models for which the assumptions utilize management’s estimates of market participant assumptions. The determination of fair value for Level 3 investments and other financial instruments involves the most management judgment and subjectivity.
Allowance for Doubtful Accounts	Allowance for Doubtful Accounts The Company establishes an allowance for doubtful accounts to ensure that its trade receivables balances are not overstated due to uncollectibility. The Company performs ongoing customer credit evaluations within the context of the industry in which it operates and generally does not require collateral from its customers. A specific allowance of up to 100% of the invoice value is provided for any problematic customer balances. Delinquent account balances are written off after management has determined that the likelihood of collection is remote. The Company grants credit only to customers deemed creditworthy in the judgment of management. The allowance for doubtful accounts was $41,000 at March 31, 2021 and December 31, 2020.
Inventories	Inventories The Company values its inventories at the lower of cost, which approximates actual cost on a first-in, first-out basis, or net realizable value. The Company records inventory reserves for estimated obsolescence or unmarketable inventories based upon assumptions about future demand and market conditions. Once a reserve is established, it is maintained until the product to which it relates is sold or otherwise disposed of. If actual market conditions are less favorable than those expected by management, additional adjustment to inventory valuation may be required. Charges for obsolete and slow-moving inventories are recorded based upon an analysis of specific identification of obsolete inventory items and quantification of slow moving inventory items. The Company recorded no material write-downs of inventory during the three months ended March 31, 2021 and recorded write-downs of $0.1 million for the year ended December 31, 2020.
Revenue Recognition	Revenue Recognition The Company generates revenue primarily from sales of IC products and licensing of its IP. Revenues are recognized when control is transferred to customers in amounts that reflect the consideration the Company expects to be entitled to receive in exchange for those goods. Revenue recognition is evaluated through the following five steps: (i) identification of the contract, or contracts, with a customer; (ii) identification of the performance obligations in the contract; (iii) determination of the transaction price; (iv) allocation of the transaction price to the performance obligations in the contract; and (v) recognition of revenue when or as a performance obligation is satisfied. IC products Revenue is recognized when performance obligations under the terms of a contract with a customer are satisfied. The majority of the Company’s contracts have a single performance obligation to transfer products. Accordingly, the recognizes revenue when title and risk of loss have been transferred to the customer, generally at the time of shipment of products. Revenue is measured as the amount of consideration the Company expects to receive in exchange for transferring products and is generally based upon a negotiated, formula, list or fixed price. The Company its and generally under agreements with payment terms typically less than 60 days. Royalty and other The Company’s licensing contracts typically provide for royalties based on the licensee’s use of the Company’s memory technology in its currently shipping commercial products. The Company estimates its royalty revenue in the calendar quarter in which the licensee uses the licensed technology. Payments are generally received in the subsequent quarter. Contract liabilities – deferred revenue The Company’s contract liabilities consist of advance customer payments and deferred revenue. The Company classifies advance customer payments and deferred revenue as current or non-current based on the timing of when the Company expects to recognize revenue. During the three months ended March 31, 2021, the Company recognized no revenue that had been included in deferred revenue as of December 31, 2020. See Note 5 for disaggregation of revenue by geography.
Cost of Net Revenue	Cost of Net Revenue Cost of net revenue consists primarily of direct and indirect costs of IC product sales and engineering personnel costs directly related to maintenance and support services specified in licensing agreements. Maintenance and support typically include engineering support to assist in the commencement of production of a licensee’s products.
Warrants	Warrants As of March 31, 2021, the Company had the following warrants outstanding (share amounts in thousands): Warrant Type Number of Shares Exercise Price Expiration Common stock 33 $ 47.00 January 2023 Common stock 813 $ 2.40 October 2023
Per Share Amounts	Per Share Amounts Basic net income (loss) per share is computed by dividing net income (loss) for the period by the weighted-average number of shares of common stock outstanding during the period. Diluted net income (loss) per share gives effect to all potentially dilutive shares of common stock outstanding during the period. Potentially dilutive shares of common stock consist of incremental shares of common stock issuable upon the exercise of stock options, vesting of stock awards and shares issuable in conjunction with convertible notes. The following table sets forth securities outstanding that were excluded from the computation of diluted net loss per share as their inclusion would be anti-dilutive (in thousands): March 31, 2021 2020 Options outstanding to purchase common stock 159 161 Unvested restricted common stock units 58 82 Convertible notes - 254 Warrants 846 1,879 Total 1,063 2,376

The Company and Summary of Si_3

The Company and Summary of Significant Accounting Policies (Tables)	3 Months Ended
	Mar. 31, 2021
Accounting Policies [Abstract]
Summary of Outstanding Warrants	As of March 31, 2021, the Company had the following warrants outstanding (share amounts in thousands): Warrant Type Number of Shares Exercise Price Expiration Common stock 33 $ 47.00 January 2023 Common stock 813 $ 2.40 October 2023
Schedule of Antidilutive Securities Excluded from Computation of Diluted Net Loss Per Share	The following table sets forth securities outstanding that were excluded from the computation of diluted net loss per share as their inclusion would be anti-dilutive (in thousands): March 31, 2021 2020 Options outstanding to purchase common stock 159 161 Unvested restricted common stock units 58 82 Convertible notes - 254 Warrants 846 1,879 Total 1,063 2,376

Fair Value of Financial Instr_2

Fair Value of Financial Instruments (Tables)	3 Months Ended
	Mar. 31, 2021
Fair Value Disclosures [Abstract]
Schedule of Estimated Fair Values of Financial Instruments Outstanding	The estimated fair values of financial instruments outstanding were (in thousands): March 31, 2021 Unrealized Unrealized Fair Cost Gains Losses Value Cash and cash equivalents $ 9,529 $ — $ — $ 9,529 Short-term investments 1,611 — (1 ) 1,610 $ 11,140 $ — $ (1 ) $ 11,139 December 31, 2020 Unrealized Unrealized Fair Cost Gains Losses Value Cash and cash equivalents $ 5,889 $ — $ — $ 5,889
Schedule of Fair Value Hierarchy for Financial Assets (Cash Equivalents and Investments)	The following table represents the Company’s fair value hierarchy for its financial assets (cash equivalents and investments) (in thousands): March 31, 2021 Fair Value Level 1 Level 2 Level 3 Money market funds $ 7,276 $ 7,276 $ — $ — Corporate notes and commercial paper $ 1,610 $ — $ 1,610 $ — December 31, 2020 Fair Value Level 1 Level 2 Level 3 Money market funds $ 3,893 $ 3,893 $ — $ —

Balance Sheet Detail (Tables)

Balance Sheet Detail (Tables)	3 Months Ended
	Mar. 31, 2021
Organization Consolidation And Presentation Of Financial Statements [Abstract]
Schedule of Inventory	March 31, December 31, 2021 2020 (in thousands) Inventories: Work-in-process $ 654 $ 414 Finished goods 208 185 $ 862 $ 599

Business Segments, Concentrat_2

Business Segments, Concentration of Credit Risk and Significant Customers (Tables)	3 Months Ended
	Mar. 31, 2021
Segment Reporting [Abstract]
Schedule of Revenue from Shipment of Product and Licensing of its Technologies to Customers by Geographical Location	The Company recognized revenue from shipment of product and licensing of its technologies to customers by geographical location as follows (in thousands): Three Months Ended March 31, 2021 2020 North America $ 948 $ 812 Japan 274 237 Taiwan 79 138 Rest of world 37 73 Total net revenue $ 1,338 $ 1,260
Schedule of Customers Who Accounted for at Least 10% of Total Net Revenue	Customers who accounted for at least 10% of total net revenue were: Three Months Ended March 31, 2021 2020 Customer A 38% 26% Customer B 20% 19% Customer C 18% 14% Customer D *% 12% Customer E *% 11% * Represents less than 10%

Stock-Based Compensation (Table

Stock-Based Compensation (Tables)	3 Months Ended
	Mar. 31, 2021
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]
Summary of Share Available for Grant Under the 2019 Plan	The following table summarizes the activity in the shares available for grant under the Plans during the three months ended March 31, 2021 (in thousands, except exercise price): Options outstanding Weighted Shares Average Available Number of Exercise for Grant Shares Prices Balance as of January 1, 2021 81 159 $ 10.82 RSUs granted (10 ) — — Balance as of March 31, 2021 71 159 $ 10.82
Summary of RSU Activity Under Plans	A summary of RSU activity under the Plans is presented below (in thousands, except for fair value): Weighted Average Number of Grant-Date Shares Fair Value Non-vested shares as of January 1, 2021 65 $ 3.48 Granted 10 $ 3.25 Vested (17 ) $ 3.78 Non-vested shares as of March 31, 2021 58 $ 3.35
Summary of Significant Ranges of Outstanding and Exercisable Options	The following table summarizes significant ranges of outstanding and exercisable options as of March 31, 2021 (in thousands, except contractual life and exercise price): Options Outstanding Options Exercisable Weighted Average Remaining Weighted Weighted Contractual Average Average Aggregate Number Life Exercise Number Exercise Intrinsic Range of Exercise Price Outstanding (in Years) Price Exercisable Price value $1.57 - $14.99 143 8.01 $ 2.62 79 $ 2.88 $ 185 $15.00 - $25.59 8 2.49 $ 15.00 8 $ 15.00 $ — $25.60 - $143.99 2 3.11 $ 41.81 2 $ 41.81 $ — $144.00 - $409.99 5 5.40 $ 144.00 5 $ 144.00 $ — $410.00 - $924.00 1 3.94 $ 430.64 1 $ 430.64 $ — $1.57 - $924.00 159 8.04 $ 10.82 95 $ 16.55 $ 185

Leases (Tables)

Leases (Tables)	3 Months Ended
	Mar. 31, 2021
Leases [Abstract]
Schedule of Future Minimum Payments under Facility Operating Lease	Future minimum payments under the facility operating lease at March 31, 2021 are as follows (in thousands): Operating Year ending December 31, lease 2021 $ 155 2022 112 Total future lease payments 267 Less: imputed interest (9 ) Present value of lease liabilities $ 258
Schedule of Supplemental Cash Flow Information Related to Operating lease	Supplemental cash flow information related to the operating lease was as follows (in thousands): Three Months Ended March 31, 2021 2020 Cash paid for amounts included in the measurement of lease liabilities: Operating cash flows for lease $ 51 $ 56

The Company and Summary of Si_4

The Company and Summary of Significant Accounting Policies - Additional Information (Details) - USD ($)	3 Months Ended	12 Months Ended
	Mar. 31, 2021	Dec. 31, 2020
Accounting Policies [Abstract]
Maximum specific allowance as percentage of invoice value for problematic customer balances	100.00%
Allowance for doubtful accounts	$ 41,000,000	$ 41,000,000
Inventory write-downs	$ 0	$ 100,000
Payment terms	The Company sells its products both directly to customers and through distributors generally under agreements with payment terms typically less than 60 days.
Deferred revenue, revenue recognized	$ 0

The Company and Summary of Si_5

The Company and Summary of Significant Accounting Policies - Summary of Outstanding Warrants (Details) - $ / shares	Mar. 31, 2021	Feb. 28, 2021
Class Of Warrant Or Right [Line Items]
Exercise Price	$ 2.40	$ 2.40
Common Stock Warrants One
Class Of Warrant Or Right [Line Items]
Number of Shares	33
Exercise Price	$ 47
Expiration	Jan. 30, 2023
Common Stock Warrants Two
Class Of Warrant Or Right [Line Items]
Number of Shares	813
Exercise Price	$ 2.40
Expiration	Oct. 30, 2023

The Company and Summary of Si_6

The Company and Summary of Significant Accounting Policies - Schedule of Antidilutive Securities Excluded from Computation of Diluted Net Loss Per Share (Details) - shares shares in Thousands	3 Months Ended
	Mar. 31, 2021	Mar. 31, 2020
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	1,063	2,376
Options Outstanding to Purchase Common Stock
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	159	161
RSU's
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	58	82
Convertible Notes
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount		254
Warrants
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	846	1,879

Fair Value of Financial Instr_3

Fair Value of Financial Instruments - Schedule of Estimated Fair Values of Financial Instruments Outstanding (Details) - USD ($) $ in Thousands	Mar. 31, 2021	Dec. 31, 2020
Debt Securities, Available-for-sale [Line Items]
Cost	$ 11,140
Unrealized Gains	0
Unrealized Losses	(1)
Fair Value	11,139
Cash and Cash Equivalents
Debt Securities, Available-for-sale [Line Items]
Cost	9,529	$ 5,889
Unrealized Gains	0	0
Unrealized Losses	0	0
Fair Value	9,529	$ 5,889
Short-term investments
Debt Securities, Available-for-sale [Line Items]
Cost	1,611
Unrealized Gains	0
Unrealized Losses	(1)
Fair Value	$ 1,610

Fair Value of Financial Instr_4

Fair Value of Financial Instruments - Schedule of Fair Value Hierarchy for Financial Assets (Cash Equivalents and Investments) (Details) - Fair Value, Measurements, Recurring - USD ($) $ in Thousands	Mar. 31, 2021	Dec. 31, 2020
Money market funds
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair Value	$ 7,276	$ 3,893
Money market funds | Level 1
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair Value	7,276	$ 3,893
Corporate notes and commercial paper
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair Value	1,610
Corporate notes and commercial paper | Level 2
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair Value	$ 1,610

Fair Value of Financial Instr_5

Fair Value of Financial Instruments - Additional Information (Details) - USD ($)	Mar. 31, 2021	Mar. 31, 2020
Fair Value Disclosures [Abstract]
Transfer of assets between Level 1 to Level 2	$ 0	$ 0
Transfer of assets between Level 2 to Level 1	0	0
Transfer of liabilities between Level 1 to Level 2	0	0
Transfer of liabilities between Level 2 to Level 1	$ 0	$ 0

Balance Sheet Detail - Schedule

Balance Sheet Detail - Schedule of Inventory (Details) - USD ($) $ in Thousands	Mar. 31, 2021	Dec. 31, 2020
Inventory Disclosure [Abstract]
Work-in-process	$ 654	$ 414
Finished goods	208	185
Total	$ 862	$ 599

Business Segments, Concentrat_3

Business Segments, Concentration of Credit Risk and Significant Customers - Additional Information (Details)	3 Months Ended	12 Months Ended
	Mar. 31, 2021SegmentCustomer	Dec. 31, 2020Customer
Business Segments
Number of business segments | Segment	1
Number of measurements of profitability	1
Accounts receivable | Major customers | Credit concentration
Business Segments
Percentage of concentration risk	74.00%	86.00%
Number of customers | Customer	3	3

Business Segments, Concentrat_4

Business Segments, Concentration of Credit Risk and Significant Customers - Schedule of Revenue from Shipment of Product and Licensing of its Technologies to Customers by Geographical Location (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2021	Mar. 31, 2020
Business Segments
Total net revenue	$ 1,338	$ 1,260
North America [Member]
Business Segments
Total net revenue	948	812
Japan [Member]
Business Segments
Total net revenue	274	237
Taiwan [Member]
Business Segments
Total net revenue	79	138
Rest of world [Member]
Business Segments
Total net revenue	$ 37	$ 73

Business Segments, Concentrat_5

Business Segments, Concentration of Credit Risk and Significant Customers - Schedule of Customers Who Accounted for at Least 10% of Total Net Revenue (Details) - Net Revenues - Customer Concentration	3 Months Ended
	Mar. 31, 2021	Mar. 31, 2020
Customer A
Significant Customers
Percentage of concentration risk	38.00%	26.00%
Customer B
Significant Customers
Percentage of concentration risk	20.00%	19.00%
Customer C
Significant Customers
Percentage of concentration risk	18.00%	14.00%
Customer D
Significant Customers
Percentage of concentration risk		12.00%
Customer E
Significant Customers
Percentage of concentration risk		11.00%

Income Tax Provision - Addition

Income Tax Provision - Additional Information (Details)	Mar. 31, 2021USD ($)
Income Tax Disclosure [Abstract]
Unrecognized tax benefits recorded as liability	$ 0

Stock-Based Compensation - Addi

Stock-Based Compensation - Additional Information (Details) - USD ($)	3 Months Ended
	Mar. 31, 2021	Mar. 31, 2020
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Options granted (in shares)	0	0
Options
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Unamortized compensation cost, net of expected forfeitures	$ 100,000
Weighted average expected period over which the expense is to be recognized	1 year 3 months
Tax benefits associated with exercise of stock options	$ 0	$ 0
Stock options exercised	0	0
RSU's
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Weighted average expected period over which the expense is to be recognized	6 months
Stock-based compensation expense, recognition period	3 years
Unamortized compensation cost, net of expected forfeitures	$ 200,000
Fair value granted	$ 32,500,000
Equity Incentive Plan 2010
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Outstanding awards	57,858,000
Equity Incentive Plan 2010 | RSU's
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Total intrinsic value of the restricted stock units outstanding	$ 200,000
Stock Incentive Plan 2019
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Number of shares reserved for issuance	182,500
Stock Incentive Plan 2019 | Options
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Maximum annual option grants or other awards to the entity's non-employee directors (in shares)	2,000
Maximum one-time grant of an option or other awards to the entity's non employee directors (in shares)	6,000
Minimum percentage of voting rights required for applicability of a specific expiration term	10.00%
Maximum expiration term of options granted	5 years
Term of plan	10 years
Stock Incentive Plan 2019 | Options | Minimum
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Vesting period of replacement options	3 years
Stock Incentive Plan 2019 | Options | Maximum
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Vesting period of replacement options	4 years

Stock-Based Compensation - Summ

Stock-Based Compensation - Summary of Share Available for Grant Under the 2019 Plan (Details) - Equity Incentive Plan 2019 shares in Thousands	3 Months Ended
	Mar. 31, 2021$ / sharesshares
Shares Available for Grant
Balance at the beginning of the year (in shares)	81
Balance at the end of the period (in shares)	71
Number of Shares
Balance at the beginning of the year (in shares)	159
Balance at the end of the period (in shares)	159
Weighted Average Exercise Prices
Weighted-average exercise price (in dollars per share) | $ / shares	$ 10.82
Weighted-average exercise price (in dollars per share) | $ / shares	$ 10.82
RSU's
Shares Available for Grant
RSUs granted (in shares)	(10)
Weighted Average Exercise Prices
RSUs granted (in dollars per share) | $ / shares	$ 3.25

Stock-Based Compensation - Su_2

Stock-Based Compensation - Summary of RSU Activity Under Plans (Details) - Equity Incentive Plan 2019 - RSU's shares in Thousands	3 Months Ended
	Mar. 31, 2021$ / sharesshares
Number of Shares
Non-vested shares at the beginning of the year | shares	65
Granted (in shares) | shares	10
Vested (in shares) | shares	(17)
Non-vested shares at the end of the period | shares	58
Weighted Average Grant-Date Fair Value
Weighted average grant date fair value | $ / shares	$ 3.48
Granted (in dollars per share) | $ / shares	3.25
Vested (in dollars per share) | $ / shares	3.78
Weighted average grant date fair value | $ / shares	$ 3.35

Stock-Based Compensation - Su_3

Stock-Based Compensation - Summary of Significant Ranges of Outstanding and Exercisable Options (Details) - Options $ / shares in Units, shares in Thousands, $ in Thousands	3 Months Ended
	Mar. 31, 2021USD ($)$ / sharesshares
$1.57 - $14.99
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Lower range limit (in dollars per share)	$ 1.57
Upper range limit (in dollars per share)	$ 14.99
Number Outstanding (in shares) | shares	143
Weighted Average Remaining Contractual Life (in Years)	8 years 3 days
Weighted Average Exercise Price (in dollars per share)	$ 2.62
Number Exercisable (in shares) | shares | shares	79
Weighted Average Exercise Price (in dollars per share)	$ 2.88
Options Outstanding, Aggregate Intrinsic Value | $	$ 185
$15.00 - $25.59
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Lower range limit (in dollars per share)	$ 15
Upper range limit (in dollars per share)	$ 25.59
Number Outstanding (in shares) | shares	8
Weighted Average Remaining Contractual Life (in Years)	2 years 5 months 26 days
Weighted Average Exercise Price (in dollars per share)	$ 15
Number Exercisable (in shares) | shares | shares	8
Weighted Average Exercise Price (in dollars per share)	$ 15
$25.60 - $143.99
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Lower range limit (in dollars per share)	25.60
Upper range limit (in dollars per share)	$ 143.99
Number Outstanding (in shares) | shares	2
Weighted Average Remaining Contractual Life (in Years)	3 years 1 month 9 days
Weighted Average Exercise Price (in dollars per share)	$ 41.81
Number Exercisable (in shares) | shares | shares	2
Weighted Average Exercise Price (in dollars per share)	$ 41.81
$144.00 - $409.99
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Lower range limit (in dollars per share)	144
Upper range limit (in dollars per share)	$ 409.99
Number Outstanding (in shares) | shares	5
Weighted Average Remaining Contractual Life (in Years)	5 years 4 months 24 days
Weighted Average Exercise Price (in dollars per share)	$ 144
Number Exercisable (in shares) | shares | shares	5
Weighted Average Exercise Price (in dollars per share)	$ 144
$410.00 - $924.00
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Lower range limit (in dollars per share)	410
Upper range limit (in dollars per share)	$ 924
Number Outstanding (in shares) | shares	1
Weighted Average Remaining Contractual Life (in Years)	3 years 11 months 8 days
Weighted Average Exercise Price (in dollars per share)	$ 430.64
Number Exercisable (in shares) | shares | shares	1
Weighted Average Exercise Price (in dollars per share)	$ 430.64
$1.57 - $924.00
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Lower range limit (in dollars per share)	1.57
Upper range limit (in dollars per share)	$ 924
Number Outstanding (in shares) | shares	159
Weighted Average Remaining Contractual Life (in Years)	8 years 14 days
Weighted Average Exercise Price (in dollars per share)	$ 10.82
Number Exercisable (in shares) | shares | shares	95
Weighted Average Exercise Price (in dollars per share)	$ 16.55
Options Outstanding, Aggregate Intrinsic Value | $	$ 185

Stockholders' Equity - Addition

Stockholders' Equity - Additional Information (Details) - USD ($)	1 Months Ended	2 Months Ended	3 Months Ended		6 Months Ended
	Feb. 28, 2021	Feb. 28, 2021	Mar. 31, 2021	Mar. 31, 2020	Feb. 15, 2021
Stockholders Equity Note [Abstract]
Number of common stock sold	1,487,601				42,672
Sale of stock, price per share	$ 5	$ 5
Net proceeds of the offering	$ 6,800,000		$ 6,817,000
Proceeds from warrant exercise		$ 1,473,098	$ 2,478,461	$ 2,000
Warrant to purchase of common stock			1,032,692
Exercise Price	$ 2.40	$ 2.40	$ 2.40

Notes Payable - Additional Info

Notes Payable - Additional Information (Details) - USD ($)	May 07, 2020	Mar. 31, 2021	Feb. 28, 2021	Aug. 31, 2020	Feb. 29, 2020	Aug. 31, 2019	Feb. 28, 2019	Oct. 31, 2018	Feb. 28, 2021	Mar. 31, 2021	Mar. 31, 2020	Feb. 15, 2021	Mar. 31, 2016
Debt Instrument [Line Items]
Payment on principle amount of note		$ 1,554,173								$ 3,027,000
Sale of common stock, net of placement costs,shares			1,487,601									42,672
Sale of common stock, net of placement costs										$ 6,817,000		$ 139,964
Gain (loss) on repayment of interest on convertible notes payable												$ (16,898)
Exercise of warrants to purchase number of shares of common stock			613,791,000						613,791,000
Exercise Price		$ 2.40	$ 2.40						$ 2.40	$ 2.40
Proceeds from exercise of common stock warrants									$ 1,473,098	$ 2,478,461	$ 2,000
Gain on note settlement		$ 64,757
Senior Secured Convertible Notes due August 15 2018
Debt Instrument [Line Items]
Stated interest rate								8.00%					10.00%
Principal amount													$ 8,000,000
Payment on principle amount of note								$ 7,400,000
Senior Secured Convertible Notes due August 15, 2023
Debt Instrument [Line Items]
Conversion price								$ 11.434					$ 170
Interest Note and Accrued Interest
Debt Instrument [Line Items]
Semi-annual interest payments				$ 122,000	$ 112,000	$ 109,000	$ 78,000
Promissory Note | Paycheck Protection Program
Debt Instrument [Line Items]
Stated interest rate	1.00%
Principal amount	$ 579,330
Debt instrument term	2 years
Monthly payment beginning date	Mar. 31, 2021
Principal payments due in 2021	$ 217,250
Principal payments due in 2022	$ 362,080

Leases - Additional Information

Leases - Additional Information (Details) $ in Millions	3 Months Ended
	Mar. 31, 2021USD ($)Lease
Leases [Abstract]
Number of operating leases outstanding | Lease	1
Lessee, operating lease, discount rate	8.00%
Operating leases expense | $	$ 53,000
Operating lease, option to extend	false

Leases - Schedule of Future Min

Leases - Schedule of Future Minimum Payments under Facility Operating Lease (Details) $ in Thousands	Mar. 31, 2021USD ($)
Leases, Operating [Abstract]
2021	$ 155
2022	112
Total future lease payments	267
Less: imputed interest	(9)
Present value of lease liabilities	$ 258

Leases - Schedule of Supplement

Leases - Schedule of Supplemental Cash Flow Information Related to Operating lease (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2021	Mar. 31, 2020
Cash paid for amounts included in the measurement of lease liabilities:
Operating cash flows for lease	$ 51	$ 56